M&A Deal Summary

Adare Pharma Solutions Acquires Orbis Biosciences

On May 4, 2020, Adare Pharma Solutions acquired life science company Orbis Biosciences

Acquisition Highlights
  • This is Adare Pharma Solutions’ 1st transaction in the Life Science sector.
  • This is Adare Pharma Solutions’ 2nd transaction in the United States.
  • This is Adare Pharma Solutions’ 1st transaction in Kansas.

M&A Deal Summary
Date 2020-05-04
Target Orbis Biosciences
Sector Life Science
Buyer(s) Adare Pharma Solutions
Deal Type Add-on Acquisition
Advisor(s) Stifel, Nicolaus & Co., Inc. (Financial)
Gunderson Dettmer (Legal)

Target

Orbis Biosciences

Lenexa, Kansas, United States
Orbis Biosciences, Inc. is a pharmaceutical manufacturing technology company focused on licensing its technology to companies to optimize their product portfolios. Orbis develops customized formulations and intellectual property for pharmaceutical product manufacture, leveraging Orbis’ novel Precision Particle Fabrication® technology platforms: Optimµm® precision encapsulation for oral delivery, StratµmTM precision encapsulation for injectable delivery, and the Unisun® platform for enabling sustained-release otic therapies. Orbis Biosciences is based in Lenexa, Kansas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Adare Pharma Solutions

Lawrenceville, New Jersey, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Adare Pharma Solutions provides enhanced medicines, creating new possibilities for improved patient health. Adare Pharma Solutions has solved complex formulation, manufacturing, and commercialization challenges, resulting in transformational medicines that deliver value to all its stakeholders. The company has a global presence with R&D, manufacturing, and commercial operations in the Unites States, Europe, and Canada. Adare Pharma Solutions was founded in 2015 and is based in Lawrenceville, New Jersey.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (Kansas) 1 of 1
Country (United States) 2 of 3
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-15 Egalet - Parvulet Technology Platform

Wayne, Pennsylvania, United States

Egalet Corp. - Parvulet Technology Platform is protected by several patents granted in the United States, Canada, and Europe with patent life ranging from five to 10 years. Using commonly used pharmaceutical excipients, the technology enables single-dose formulation of taste-masked, easy-to-swallow oral medications with a soft food like texture for pediatric and geriatric populations (including those with dysphagia). One of the unique features of the technology is its ability to enable high dose regimens that may not be feasible by other means.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-18 Viactiv

Greenwich, Connecticut, United States

Viactiv line of supplement chews for bone health, immune health and other applications. Currently marketed through many retailers, including, among others, Walmart (retail and online), Target and Amazon, the Viactiv product lines are expected to become Guardion’s most prominent product lines, as well as to provide access to significant opportunities in the short-term for growth and expansion. Viactiv is based in Greenwich, Connecticut.

Sell -
Mergr

Product

Company

Legal